RayKnowChina Research Map
Shortlist

Shenyang

Shenyang Northern Hospital

Listed for 1 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Shenyang Northern Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Coronary heart disease冠心病0 papers led4 open trials led

Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Hepatocellular carcinoma, Stomach cancer, Lung cancer, Pancreatic cancer, Breast cancer, Glioma, Hepatoblastoma, Retinoblastoma, Chordoma, Osteosarcoma, Gastrointestinal stromal tumour, Neuroblastoma, Ewing sarcoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Lymphoma, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Congenital heart disease, Scoliosis, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Other diseases

Coronary heart disease

冠心病

Led no English-language PubMed papers on coronary heart disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
14
any status, ClinicalTrials.gov
Open trials led
4
recruiting or about to
Open trials as a site
0
led by another institution

4 hospitals in Shenyang for coronary heart disease231 hospitals in China for coronary heart disease

Open trials with this hospital 4

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Precision Colchicine Intervention to Suppress Atherosclerosis in TET2 Clonal Hematopoiesis
    Phase
    Phase 4
    Started
    2026-06
    Posted
    Registry
    NCT07362966

    Age 40 years to 85 years (registered criteria)

    Led by Shenyang Northern HospitalShenyang

  2. Recruiting
    Clinical Outcomes of Patients With Coronary Artery Disease
    Phase
    Not given
    Started
    2024-02
    Posted
    Registry
    NCT06216847

    Age 18 years to Not stated (registered criteria)

    Led by Shenyang Northern HospitalShenyang

  3. Not yet recruiting
    Safety and Efficacy of De-escalation Dual Antiplatelet Therapy After BioFreedom™ Stenting in ACS Patients With Moderate-to-high Ischemic and High Bleeding Risk
    Phase
    N/A
    Started
    2026-03
    Posted
    Registry
    NCT07374718

    Age 18 years to Not stated (registered criteria)

    Led by Shenyang Northern HospitalShenyang

  4. Not yet recruiting
    Optimization and Validation of Quality Control Indicators for Coronary Revascularization Based on Antiplatelet Therapy
    Phase
    Not given
    Started
    2025-12
    Posted
    Registry
    NCT07354828

    Age 18 years to Not stated (registered criteria)

    Led by Shenyang Northern HospitalShenyang

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

All its trials on ClinicalTrials.gov, any status18
  1. Safety and Efficacy of De-escalation Dual Antiplatelet Therapy After BioFreedom™ Stenting in ACS Patients With Moderate-to-high Ischemic and High Bleeding RiskNot yet recruitingNCT07374718Lead sponsorN/AStart 2026-03
  2. Precision Colchicine Intervention to Suppress Atherosclerosis in TET2 Clonal HematopoiesisRecruitingNCT07362966Lead sponsorPhase 4Start 2026-06
  3. Optimization and Validation of Quality Control Indicators for Coronary Revascularization Based on Antiplatelet TherapyNot yet recruitingNCT07354828Lead sponsorStart 2025-12
  4. Clinical Outcomes of Patients With Coronary Artery DiseaseRecruitingNCT06216847Lead sponsorStart 2024-02
  5. CHD Patient's Concern on Cardiac RehabilitationCompletedNCT05099692Lead sponsorStart 2021-10
  6. Dabigatran Versus Warfarin With NVAF Who Undergo PCIStatus unknownNCT03536611Lead sponsorPhase 4Start 2018-09
  7. The Optimal Strategy of Switching From Clopidogrel to Ticagrelor in Patients With Complexity of Coronary Artery DiseaseCompletedNCT03577652Lead sponsorN/AStart 2017-07
  8. Mono- Versus Dual antiPlatelet Therapy During 6-12 Months After New Generation Drug Eluting Stent ImplantationCompletedNCT03198741Lead sponsorPhase 4Start 2017-07
  9. Optimal Antiplatelet Therapy for Chinese Patients With Coronary Artery DiseaseCompletedNCT01735305Lead sponsorStart 2012-11
  10. Study of Policosanol to Improve Platelet Reactivity After Percutaneous Coronary Stent Implantation (PCI)CompletedNCT01371058Lead sponsorPhase 4Start 2011-03
  11. Efficacy and Safety of the YUKON Drug Eluting Stent in Diffuse Coronary Artery DiseaseStatus unknownNCT01418794Lead sponsorPhase 4Start 2010-10
  12. Effects of Atorvastatin Versus Pravastatin on Platelet Inhibition by ClopidogrelCompletedNCT00405717Lead sponsorPhase 4Start 2006-02
  13. Effects of Optimized Antiplatelet Treatment After Percutaneous Coronary InterventionCompletedNCT00404781Lead sponsorPhase 4Start 2006-06
  14. Safety and Efficacy of Six Months Dual Antiplatelet Therapy After Drug-Eluting StentingStatus unknownNCT00661206Lead (inferred)Phase 4Start 2008-09
  15. EXCEL-II DES to Treat the Patients With de Novo Coronary Artery Lesions. (CREDIT-III)CompletedNCT02027870Study siteStart 2014-01
  16. EXCEL-II Stent Vesus EXCEL Stent to Treat the Patients With de Novo Coronary Artery Lesions.CompletedNCT02057978Study siteStart 2013-12
  17. A Pilot First In Man Study of EXCEL-Ⅱto Treat the Patients With de Novo Coronary Artery LesionsCompletedNCT01909869Study siteN/AStart 2013-01
  18. The EVOLVE China Clinical TrialCompletedNCT01966159Study siteN/AStart 2013-10

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

Shenyang Northern Hospital

沈阳

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

No hospital-level ROR record matched.

Suggest a correctionDownload the data